For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Moderna Shares Recover After Decline Following Cancer Vaccine Success

Aug 25, 2026
Moderna Shares Recover After Decline Following Cancer Vaccine Success

(NASDAQ:) shares experienced a 2.9% increase in pre-market trading, marking a recovery after several sessions of decline. This decline followed a notable rally sparked by encouraging Phase 3 trial results for its personalized mRNA cancer vaccine, intismeran autogene. The trial demonstrated a significant reduction in melanoma recurrence among patients whose tumors had been surgically removed, representing a milestone as the first successful late-stage trial for an mRNA-based cancer vaccine.

The initial excitement surrounding the trial results led to a sharp increase in Moderna's stock price, but recent profit-taking has tempered this rally. Investors are now reassessing the commercial potential and associated risks of the treatment in light of the initial enthusiasm.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

Analyst commentary has provided additional support for Moderna's stock ahead of the market's opening. Barclays analyst Eliana Merle raised the price target for Moderna to $125 from $48 while maintaining an Equal Weight rating. This significant increase in the target price reflects the positive Phase 3 results for intismeran.

Wolfe Research also upgraded Moderna from Underperform to Peerperform following the trial data, estimating potential unadjusted peak sales of $9.2 billion across four indications: adjuvant melanoma, renal cell carcinoma (RCC), muscle-invasive bladder cancer (MIBC), and non-small cell lung cancer (NSCLC), not accounting for Moderna's profit-sharing arrangement with Merck.

Despite these favorable assessments, investors remain cautious as they evaluate the commercial prospects of intismeran and whether the vaccine can convert its clinical success into substantial revenue.

The recent rebound in Moderna's shares comes after a remarkable year, with the stock gaining approximately 392% year to date following the successful Phase 3 melanoma trial. This surge has been accompanied by significant volatility, as the initial positive response to the trial results was followed by profit-taking and weakness in parts of the sector.

Merck, Moderna's partner in the development of intismeran, has also seen benefits from the optimism surrounding the program. Investors across the biotechnology sector are reassessing the implications of the first positive Phase 3 result for an mRNA .

The broader market conditions on Tuesday were also favorable, with the Nasdaq Composite rising by 1.0% and the S&P 500 gaining 0.5%, creating a supportive environment for higher-risk biotechnology stocks.

The combination of a stronger market, the significant price target increase from Barclays, and the stabilization following Moderna's recent correction contributed to the stock's rise in pre-market trading. Attention is now focused on the potential commercial pathway for intismeran, with analysts suggesting that 2027 could be a target year for commercialization if the program continues to yield positive data and navigates the necessary regulatory processes.

This long-term opportunity continues to attract interest in Moderna, although the stock remains below its 52-week high of $176.66 after a period of notable volatility.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Stock Market Outlook: Top Picks for November 16-20, 2026
Breaking Market News Nov 15, 2026

Stock Market Outlook: Top Picks for November 16-20, 2026

This article discusses stock market recommendations for the week of November 16-20, 2026, highlighting APL Apollo Tubes and Nykaa as top…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)